Proyectos destacados

Red transpirenaica de terapias avanzadas en linfoma no Hodgkin (THERAVLINFO)

Investigador/a principal: Patricia Pérez Galán.
Código: EFA 123/1.

Duración: 01/01/2024 - 31/12/2025
Vascularized lymphoma on-chip: a multifaceted tool for translational research (MyLymphoTool)

Código: HR22-00395.

Duración: 01/12/2022 - 30/11/2025
Dual CD19-CAR-T approaches to counteract antigen escape and tumor microenvironment immune suppression in FL

Código: INT_Milken_FLF_22.

Duración: 01/12/2022 - 30/11/2024
Vascular and extracellular matrix remodeling in follicular lymphoma: implications in the transformation to an aggressive lymphoma and immunotherapy efficacy (VASCEM_LYMPHO)

Código: PID2021-124894OB-I00.

Duración: 01/09/2022 - 31/08/2025
Patient Derived Organoids 2.0: Annotated immunocompetent organoid platforms in solid and hematological tumors as living labs for the optimization and design of current and novel immunotherapies and cellular therapies. CIBERONC (Strategic Action-Towards Ca

Investigador/a principal: Patricia Pérez Galán.
Duración: 01/07/2021 - 01/07/2023
Characterization of duvelisib activity in follicular lymphoma and macrophages crosstalk

Investigador/a principal: Patricia Pérez Galán.
Financiador: Janssen Pharmaceuticals .

Duración: 01/01/2020 - 31/12/2020
Multi-cellular interactions in the progression of chronic inflammatory diseases and lymphoproliferative disorders: 3D models to investigate targeted immune therapies -3DIMMUNETARGET

Investigador/a principal: Maria Cinta Cid Xutgla, Patricia Pérez Galán.
Financiador: Ministerio de Economia y Competitividad (MINECO) .

Código: SAF 2017- 88275-R.

Duración: 01/01/2018 - 31/12/2020
Cross-border network of personalized immunotherapies in Non-Hodgkin Lymphoma -IMLINFO (POCTEFA-INTERREG).

Investigador/a principal: Patricia Pérez Galán.
Financiador: INTERREG V-POCTEFA .

Código: EFA281/16.

Duración: 01/01/2018 - 31/12/2021
Crosstalk between lymphocytes and their microenvironment in chronic inflammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention

Investigador/a principal: Patricia Pérez Galán.
Financiador: Ministerio de Economía y Competitividad .

Código: SAF 2014/57708R.

Duración: 01/01/2015 - 01/01/2018
Characterization of the mechanisms of microenvironment-derived resistance to GS-1101/ Idelalisib in follicular lymphoma. Analysis of therapeutic potential combination with other kinases inhibitors

Investigador/a principal: Patricia Pérez Galán.
Financiador: Gilead .

Duración: 01/07/2014

La investigación de este grupo se puede llevar a cabo gracias a los financiadores.

Proyectos destacados

Red transpirenaica de terapias avanzadas en linfoma no Hodgkin (THERAVLINFO)

Vascularized lymphoma on-chip: a multifaceted tool for translational research (MyLymphoTool)

Dual CD19-CAR-T approaches to counteract antigen escape and tumor microenvironment immune suppression in FL

Vascular and extracellular matrix remodeling in follicular lymphoma: implications in the transformation to an aggressive lymphoma and immunotherapy efficacy (VASCEM_LYMPHO)

Patient Derived Organoids 2.0: Annotated immunocompetent organoid platforms in solid and hematological tumors as living labs for the optimization and design of current and novel immunotherapies and cellular therapies. CIBERONC (Strategic Action-Towards Ca

Characterization of duvelisib activity in follicular lymphoma and macrophages crosstalk

Multi-cellular interactions in the progression of chronic inflammatory diseases and lymphoproliferative disorders: 3D models to investigate targeted immune therapies -3DIMMUNETARGET

Cross-border network of personalized immunotherapies in Non-Hodgkin Lymphoma -IMLINFO (POCTEFA-INTERREG).

Crosstalk between lymphocytes and their microenvironment in chronic inflammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention

Characterization of the mechanisms of microenvironment-derived resistance to GS-1101/ Idelalisib in follicular lymphoma. Analysis of therapeutic potential combination with other kinases inhibitors

Principales financiadores